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Introduction: Theta burst pattern repetitive transcranial magnetic stimulation (TBS) is increasingly
applied to treat depression. TBS's brevity is well-suited to application in accelerated schedules. Sizeable
trials of accelerated TBS are lacking; and optimal TBS parameters such as stimulation intensity are not
established.
Methods: We conducted a three arm, single blind, randomised, controlled, multi-site trial comparing
accelerated bilateral TBS applied at 80 % or 120 % of the resting motor threshold and left unilateral 10 Hz
rTMS. 300 patients with treatment-resistant depression (TRD) were recruited. TBS arms applied 20
bilateral prefrontal TBS sessions over 10 days, while the rTMS arm applied 20 daily sessions of 10 Hz
rTMS to the left prefrontal cortex over 4 weeks. Primary outcome was depression treatment response at
week 4.
Results: The overall treatment response rate was 43.7 % and the remission rate was 28.2 %. There were no
significant differences for response (p ¼ 0.180) or remission (p ¼ 0.316) across the three groups. Response
rates between accelerated bilateral TBS applied at sub- and supra-threshold intensities were not
significantly different (p ¼ 0.319). Linear mixed model analysis showed a significant effect of time
(p < 0.01), but not rTMS type (p ¼ 0.680).
Conclusion: This is the largest accelerated bilateral TBS study to date and provides evidence that it is
effective and safe in treating TRD. The accelerated application of TBS was not associated with more rapid
antidepressant effects. Bilateral sequential TBS did not have superior antidepressant effect to unilateral
10 Hz rTMS. There was no significant difference in antidepressant efficacy between sub- and supra-
threshold accelerated bilateral TBS.
© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).novation in Mental Health,
Monash University, Camber-
Inc. This is an open access article u1. Introduction
Major depressive disorder (MDD) is a common psychiatric
illness associated with high mortality and morbidity, which can be
difficult to treat with conventional psychotherapeutic and phar-
macological approaches [1]. Treatment resistance rates of up tonder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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those living with depression, along with carer burden and health
economic costs. Repetitive transcranial magnetic stimulation
(rTMS) is a non-invasive brain stimulation technique that has been
extensively investigated and established as an effective therapy for
treatment-resistant depression (TRD) [3e6]. rTMS applies localised
electromagnetic pulses to superficial neurons of the cerebral cortex,
causing repeated neuronal depolarisation, in turn altering neuronal
excitability [7e9]. Evidence from early neuroimaging studies of
depressed patients identified aberrant blood flow/metabolic ac-
tivity in the prefrontal cortices [10e12], hence its initial selection as
a site to apply rTMS to treat this mood disorder. rTMS modulates
prefrontal regional excitability and induces changes in functional
connectivity and downstream electrophysiological effects along the
frontostriatal and limbic brain networks that the prefrontal cortical
neurons project to [13]. These changes are hypothesised to under-
pin rTMS's mechanisms of action [14e16].
A novel patterned form of rTMS, theta burst stimulation (TBS),
applies triplet bursts of gamma frequency (50 Hz) pulses at theta
frequency (5 Hz) intervals. TBS appears to induce similar effects as
standard rTMS but with markedly less time demands [17e20]. Two
forms of TBS have been described: intermittent TBS (iTBS), where
2 s of 50/5 Hz TBS are applied every 10 s over 192 s (600 total
pulses) and continuous TBS (cTBS), where 50/5 Hz TBS is applied
continuously for 40 s (600 total pulses). Whereas iTBS induces
neuronal excitatory effects similar to high-frequency (10e20 Hz)
rTMS and is typically applied to the left prefrontal cortex to treat
depression, cTBS appears to have an opposite, suppressive effect on
neuronal excitability akin to low-frequency (1 Hz) rTMS [18,21],
typically applied to the right prefrontal cortex to treat depression.
The definitive THREE-D study demonstrated once-daily left-sided
iTBS's non-inferiority relative to 10 Hz rTMS [22], leading to its
approval by the U.S. Food and Drug Administration (FDA) for the
treatment of TRD [23]. With respect to tolerability, TBS has not been
found to have poorer safety profile or higher rates of adverse events
relative to standard rTMS approaches [24].
The antidepressant efficacy of iTBS [25,26], cTBS [27e29] and
bilateral TBS, where cTBS and iTBS are applied sequentially to,
respectively, the right and left prefrontal cortices [30e32], have
been reported and summarised in recent reviews [33e35]. To date,
the only randomised trial that evaluated all three TBS approaches
head-to-head showed superior treatment response favouring
bilateral TBS (66.7 %) over left-sided iTBS (40.0 %) and right-sided
cTBS (25.0 %) [30], although this needs to be considered in the
context of the study's small sample size. In a large network meta-
analysis combining the results of 113 non-surgical brain stimula-
tion trials in the treatment of acute depression, Mutz et al. sug-
gested bilateral TBS's antidepressant potential (Odds ratio (OR)
4.44, 95 % CI 1.47e13.41) may be superior to high frequency left-
sided rTMS (OR 3.17, 95 % CI 2.29e4.37) and left iTBS (OR 3.20,
95 % CI 1.45e7.08), relative to sham stimulation [36]. Given bilateral
TBS's antidepressant potential and posited antidepressant superi-
ority over unilateral, left-sided TBS and rTMS approaches, empirical
validation by means of a prospective comparison was warranted.
In addition to stimulation site and TBS type, evaluation of TBS's
stimulation parameters, such as the stimulation pulse count and
intensity, may also improve its antidepressant efficacy and deserves
systematic investigation. With respect to the latter, TBS studies in
depression have tended to apply TBS at sub- or at-threshold in-
tensities (80e100 %) relative to patients' resting motor thresholds
(RMT) [34], while the THREE-D study applied iTBS at 120 % RMT
[22]. In preclinical studies, Nettkoven et al. reported increased
motor cortical conditioning effects of 90 % and 110% RMT iTBS in
healthy controls relative to other stimulation intensities, particu-
larly with progressively longer iTBS durations [37]. Chung et al.1096investigated iTBS's impact when applied at different intensities to
the prefrontal cortex and found 75 % RMT iTBS yielded superior
neuronal conditioning effects relative to 50 % and 100 % RMT iTBS
[38]. In therapeutic applications, however, it remains undeter-
mined whether supra- or sub-threshold TBS has superior antide-
pressant efficacy. This formed one of the key research questions for
this study.
In its current form, a standard course of rTMS involves daily
treatment sessions over 4e6 weeks. This limits its clinical appli-
cability and presents logistical challenges. The application of rTMS
may be accelerated with intensive treatment schedules applying
multiple treatments per day. Whilst accelerated rTMS trials show
therapeutic potential [39e42], the scheduling of multiple rTMS
treatments, each lasting 30 min or more, can also be time
consuming and practically cumbersome [43]. TBS's brevity of
application suggests it could be conveniently applied in intensive/
accelerated schedules, in turn reducing the duration of treatment
courses. In our pilot study, we found accelerated iTBS to have
similar antidepressant efficacy as 10 Hz rTMS applied daily over 4
weeks, but there was no shortening of the time to response [44].
Elsewhere, accelerated TBS's antidepressant potential have also
been described [45e47]. A large, definitive trial evaluating accel-
erated TBS in depression, however, remains to be done.
There is clear merit in optimising rTMS's efficacy and efficiency
to treat depression. We therefore sought to investigate the anti-
depressant and anxiolytic effects of accelerated bilateral TBS and
the speed of response, compared with a standard, FDA-approved
rTMS protocol that applied daily treatments [48]. To this end, we
devised a trial protocol that combined accelerated TBS scheduling
(deemed feasible by our pilot accelerated iTBS study [44]), and
bilateral prefrontal stimulation, on the assumption that bilateral
TBS might yield superior antidepressant efficacy over a standard
left-sided 10 Hz rTMS protocol [30,36]. Our primary hypothesis was
that accelerated bilateral TBS would have superior antidepressant
efficacy over left-sided daily 10 Hz rTMS in TRD. Comparison of
supra- (120 % RMT) and sub-threshold (80 % RMT) TBS's antide-
pressant efficacy was another key study aim. Based on findings
from the aforementioned preclinical studies, we hypothesised 80 %
RMT TBS would have superior antidepressant efficacy.
2. Methods
2.1. Study design
This was a parallel design, three arm, single blind, randomised,
controlled trial conducted across three mental health services in
three Australian states. Two sites were outpatient TMS services
(The Adelaide Clinic, South Australia, and The Gold Coast University
Hospital, Queensland) while the lead coordinating site provided
TMS treatment in an inpatient setting (Epworth Camberwell, Vic-
toria). Participants were randomised to one of three groups
(Tables 1 and 2) using a computer-generated single random num-
ber sequence: 1) Daily 10 Hz rTMS applied to the left dorsolateral
prefrontal cortex (DLPFC) over 4 weeks to serve as an active control
arm, 2) Low intensity (80 % RMT) sequential cTBS and iTBS applied
to the right then left DLPFC in a 10-day accelerated schedule, which
included a three-day break between the first and second weeks of
treatment (24,000 pulses), or 3) High intensity (120 % RMT)
sequential cTBS and iTBS applied to the right then left DLPFC in the
same 10-day accelerated schedule (24,000 pulses). Daily 10 Hz
rTMS adopted a standard, FDA-approved protocol: 75  4-s trains
applied daily to the left DLPFC [48], delivering 20 daily treatments
over 4-weeks (60,000 pulses). Twenty sessions of 10 Hz rTMS or
bilateral TBS were administered across all treatment arms. TBS
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for iTBS
1200 20 24,000
BL ¼ bilateral; cTBS ¼ continuous theta burst stimulation; DLPFC ¼ dorsolateral prefrontal cortex; Hz ¼ Hertz; iTBS ¼ intermittent theta burst stimulation; min ¼ minute.
RMT ¼ resting motor threshold; rTMS ¼ repetitive transcranial magnetic stimulation; s ¼ seconds.
TBS ¼ theta burst stimulation.
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min lapsed before the next cTBS/iTBS session was administered.
Participants and clinicians administering the rTMS were aware of
the treatment allocation, while the clinical raters remained blinded.
Participants were informed at study commencement and reminded
prior to each clinical assessment to not disclose their treatment
schedule or type to the raters. This study was centrally approved by
the Monash Health Human Research Ethics Committee and the
Research Governance Offices at the study sites (Epworth Health-
Care, Ramsay Health and Queensland Health). This study was
registered on the Australian New Zealand Clinical Trials Registry
(ANZCTR), Trial ID: 12617001443381.2.2. Participants
Participants were recruited by referrals from treating clinicians
or self-referrals in response to the trial's registration on ANZCTR. All
participants were diagnosed with MDD or bipolar disorder (majorTable 2
Schedule of rTMS/accelerated TBS treatments and clinical assessments.
Baseline Week 1 Week 2
Treatment groups
1. Standard rTMS 1 session per day over 5 days 1 session per da
2. Accelerated BL TBS Low-
Intensity
11 sessions.
2 sessions applied on Day 1.
3 sessions applied on Days 2
e4.








3. Accelerated BL TBS High
-Intensity
11 sessions.
2 sessions applied on Day 1.
3 sessions applied on Days 2
e4.










QIDS-C16 X X X
QIDS-SR16 X X X
BAI X X X
SSI X X X
EQ-5D-3L X X X
BAI ¼ Beck's Anxiety Inventory.
BL ¼ bilateral.
EQ-5D-3L ¼ EQ-5D Health Questionnaire.
MINI ¼ Mini International Neuropsychiatric Interview.
QIDS-C16 ¼ Quick Inventory of Depressive Symptomatology e Clinician Rated Version.
QIDS-SR16 ¼ Quick Inventory of Depressive Symptomatology e Self Rated Version.
SSI ¼ Scale for Suicidal Ideation; rTMS ¼ repetitive transcranial magnetic stimulation; T
1097depressive episode (MDE)) by their referring doctor and/or the
study psychiatrist. Diagnoses were confirmed using the Mini In-
ternational Neuropsychiatric Interview (MINI) [49]. Inclusion
criteria for the study were: adults over the age of 18, confirmed
diagnoses of MDE or MDD, score of 10 (moderate depression) on
the Quick Inventory of Depressive Symptomatology e Clinician
Rated Version (QIDS-C16) [50,51], and at least Stage II TRD defined
by the Thase and Rush classification [52]. Exclusion criteria
included participants who had an absolute contraindication to
rTMS, were pregnant or breastfeeding or had a clinically significant
substance use disorder. All participants were on stable antide-
pressant regimes or no antidepressant therapy for at least 4 weeks
prior to treatment commencement and until week 4 follow-up. For
participants who had previously received rTMS or ECT, at least four
weeks had lapsed since their last session of ECT or rTMS prior to
recruitment. Participants who had previously received and not
derived antidepressant benefit with left-sided 10 Hz rTMS were
excluded.Week 3 Week 4 Week 8e10
follow-up
y over 5 days 1 session per day over 5
days
1 session per day over 5
days
ed on Day 1.
ed on Days 2
ed by 15-min
ed on Day 1.







BS ¼ theta burst stimulation.
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rTMS was administered with figure-of-8 coils using the Mag-
Venture MagPro R30 stimulator with the Cool-B65 coil (MagVen-
ture Inc., Farum, Denmark) at the inpatient treatment site (Epworth
Camberwell) and the Neurosoft MS/D stimulator with the AFEC-02-
100-C coil (Neurosoft, Ivanovo, Russia) at the outpatient treatment
sites (Adelaide Clinic and Gold Coast University Hospital). The coils
were held by stands and tangentially placed over the participant's
DLPFC, rotated at a 45 angle from the midline. Coil localisationwas
conducted using the algorithm developed by Beam et al. [53].
Treatment coils were placed over the F3 electrode when targeting
the left DLPFC and the F4 electrode for the right DLPFC. Single pulse
TMS was used to measure the RMT for the abductor pollicis brevis
muscle (APB) using standard published methods and direct visu-
alisation of APB movement [54]. Bilateral RMTs were measured for
participants randomised to accelerated bilateral TBS. Training in all
trial and treatment processes was provided by the lead site for the
three study sites.
2.4. Clinical assessment
Demographic and illness variables and clinical ratings were
recorded at baseline. Subsequent clinical assessments were con-
ducted 1, 2, 4 and 8 weeks after treatment commencement for all
participants (Table 2). This meant that for those randomised to
standard 10 Hz rTMS treatment, the week 4 assessments took place
on course completion and for those randomised to accelerated
bilateral TBS protocols, 18-days after course completion, given the
accelerated bilateral TBS courses were 10-days in duration.
Depression severity was assessed using the QIDS-C16 and the Quick
Inventory of Depressive Symptomatology e Self-Rated Version
(QIDS-SR16) [50]. Health-related quality of life was assessed using
the EQ-5D Health Questionnaire [55] and single summary indices
were calculated using the Australian value set [56]. Presence/
severity of suicidal thinking was assessed using the Scale for Sui-
cidal Ideation (SSI) [57]. A protocol amendment added the 21-item
self-report Beck's Anxiety Inventory (BAI) [58] during the trial to
measure anxiety severity.
2.5. Data analysis
Primary analysis was comparison of the proportion of treatment
responders 4 weeks after treatment commencement using the Х2
test. Treatment response was defined as  50 % reduction in the
QIDS-C16 from baseline while remission was defined as a QIDS-C16
score of 5 [50]. Seeing as end of treatment would be different for
those who received accelerated bilateral TBS compared with once-
daily 10 Hz rTMS, we conducted a sensitivity analysis at week 2 by
comparison of response rates across the three treatment groups
using the Х2 test (Supplementary). Х2 tests were also conducted to
compare treatment response between the low- and high-intensity
accelerated bilateral TBS groups and the proportion of treatment
responders across the three groups at week 8 follow-up. Linear
Mixed Model Analyses using restricted maximum likelihood
(REML) were applied with Fixed Effects of Group and Timewith the
covariance structure treated as unstructured for all continuous
outcome measures. This statistical method assesses changes over
time and is robust to violations of normality [59]. It also handles
missing values by treating them as missing at random, rather than
listwise deletion. The F-test was used to evaluate if there were
between-group differences and test for interactions by Time and by
Treatment Group. The Bonferroni test was used for post-hoc1098comparisons between treatment groups at each time point. These
utilise the predicted means and standard errors of difference that
are recovered from the fitted mixed model. Diagnostic plots of re-
siduals were assessed to ensure normal distribution criteria were
met and variance stabilising transformations applied if not. All
analyses were conducted using SPSS 25.0 (IBM SPSS Statistics for
Windows. Armonk, NY: IBM Corp; 2017).
3. Results
3.1. Patients
300 eligible participants were recruited and consented, as
detailed in the CONSORT Flowchart (Fig. 1). There were no notable
differences in demographic or clinical variables (Table 3), with
specific comparisons between in- and outpatients included as
supplementary material. 295 participants entered treatment and
252 participants completed treatment and week 4 assessment.
Four participants allocated to the 120 % RMT accelerated bilateral
TBS treatment group withdrew from the trial due to difficulty
tolerating the stimulation sensation. It was not noted if the intol-
erance was specifically to cTBS or iTBS. Means of assessment vari-
ables across the three groups over each assessment timepoint are
presented in Table 4. Sensitivity analysis at week 2 did not identify
significant differences in response rates across the three groups.
3.2. Primary outcome e comparison of week 4 QIDS-C16 responders
We found an overall response rate of 43.7 % (110/252) and
remission rate of 28.2 % (71/252). The proportion of patients who
met QIDS-C16 response or remission criteria at week 4 did not differ
to a statistically significant extent across the three groups
(response: Х2 ¼ 3.429, p ¼ 0.180, remission: Х2 ¼ 2.303, p ¼ 0.316)
(Table 5). Similarly, there were no statistically significant differ-
ences in response and remission rates between the inpatient and
outpatient cohorts (response: Х2 ¼ 0.969, p ¼ 0.325, remission:
Х2 ¼ 0.157, p ¼ 0.692) (Table 5). Findings in sensitivity analyses
were largely consistent with the main Х2 tests, with no significant
differences in response and remission rates between treatment
groups at week 2 (Supplementary).
3.3. Low-intensity vs high-intensity TBS
Comparing low-intensity (80 % RMT) with high-intensity (120 %
RMT) accelerated bilateral TBS, we found no significant difference
in week 4 QIDS-C16 response (Х2 ¼ 0.995, p ¼ 0.319) or remission
rates (Х2 ¼ 0.178, p ¼ 0.673).
3.4. Responders at week 8 follow-up
Due to resource constraints, follow-up until week 8 was not
possible for the majority of our outpatient participants. However,
QIDS-C16 measures at week 8 assessment were available for anal-
ysis in 85 of the 116 participants who received rTMS/TBS as in-
patients. For these, 43.5 % (37/85) remained in treatment response
and 29.4 % (25/85) remained in remission (Table 6). There were no
significant differences across the three treatment groups.
3.5. Change in depression severity over time
Applying the linear mixed model to the QIDS-C16 scores found a
significant main effect of Time (F (4, 200.65) ¼ 136.92, p < 0.001).
There was no effect by Treatment Group (F (2, 276.89) ¼ 0.38, p ¼
Fig. 1. CONSORT diagram.
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and Treatment Group (F (8, 200.61) ¼ 2.78, p ¼ 0.006). Post-hoc
comparisons using the Bonferroni test indicated that the mean
QIDS-C score at week 4 in the standard rTMS group was signifi-
cantly lower compared to the low-intensity TBS; t (118.98) ¼ 2.62,
p ¼ 0.01 and high-intensity TBS groups; t (118.61) ¼ -3.65, p <
0.001. There were no significant differences between the treatment
groups at any other time points. Fig. 2 shows reduction in the QIDS-
C16 mean scores for the three treatment arms at each assessment
timepoint. Fig. 3 delineates depression reduction trajectories by
treatment groups and in-/out-patient settings.Table 3












Duration of current episodes (months) 48.13
Number of depressive episodes 5.06
Age of illness onset 25.59
Number of antidepressants 8.15
Number of other drugs 1.68
Past ECT (Y/N) 26/58
Responder to ECT (Y/N) 16/10
Antidepressant (Y/N) 66/16
Antipsychotic (Y/N) 30/51
Mood stabiliser (Y/N) 20/58
Stimulator allocation (MagVenture (Inpatients))/Neurosoft (Outpatients)) 30/54
Bipolar I ¼ bipolar affective disorder e type 1; Bipolar II ¼ bipolar affective disorder e t
10993.6. Anxiety
There was no significant difference across the three rTMS ap-
proaches in reducing anxiety severity from baseline to week 4 and
8 (Fig. 4). Linear mixed model analysis found a significant effect on
anxiety severity by Time (F (4, 87.45) ¼ 25.11, p < 0.001), but not by
Treatment Group (F (2, 109.59) ¼ 0.01, p ¼ 1.00).3.7. QIDS-SR16, suicidality and quality of life
The same linear mixed model was used to analyse the contin-
uous variables of our secondary outcome measures. For the QIDS-rd Low intensity High intensity
r Frequency SD Mean or Frequency SD Mean or Frequency SD








105.91 56.70 104.00 47.91 80.30
5.77 6.10 9.25 6.55 8.60
14.85 24.90 13.06 27.64 14.92
5.65 8.15 5.12 8.68 6.15







ype 2; ECT ¼ electroconvulsive therapy; MDD ¼ major depressive disorder.
Table 4
Mean scores of clinical assessments across the 3 treatment groups at each timepoint.
Baseline Week 1 Week 2 Week 4 Week 8
n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD
QIDS-C16 Standard rTMS 84 16.58 3.82 70 12.84 5.46 73 10.89 4.93 72 9.40 5.58 29 11.00 6.19
Low intensity TBS 107 16.89 4.06 99 12.81 5.20 101 11.48 5.22 93 11.06 5.51 40 10.30 5.96
High intensity TBS 101 17.40 3.68 93 13.22 4.77 90 11.38 5.64 88 11.80 5.73 39 10.21 5.20
QIDS-SR16 Standard rTMS 83 16.43 4.85 73 11.97 5.72 76 10.41 5.60 70 9.79 6.31 28 10.86 6.50
Low intensity TBS 103 16.97 5.10 100 12.38 5.53 97 11.10 5.70 88 10.72 6.32 38 11.08 5.99
High intensity TBS 100 16.90 4.24 92 12.49 5.31 89 11.52 6.27 84 11.79 6.42 36 10.56 5.46
SSI Standard rTMS 84 8.69 8.93 73 6.23 8.62 76 5.00 7.74 71 4.18 7.50 28 3.86 7.51
Low intensity TBS 103 10.12 10.49 99 7.59 9.72 95 6.93 9.18 88 5.94 8.83 36 8.06 10.08
High intensity TBS 99 8.26 9.10 88 5.18 7.30 87 4.79 6.89 83 4.87 7.19 35 3.83 5.86
EQ-5D Standard rTMS 84 0.47 0.25 73 0.60 0.24 76 0.59 0.23 70 0.65 0.25 30 0.66 0.25
Low intensity TBS 104 0.50 0.22 103 0.61 0.24 97 0.62 0.24 88 0.66 0.22 41 0.62 0.26
High intensity TBS 99 0.50 0.22 93 0.59 0.20 89 0.62 0.21 84 0.61 0.23 35 0.66 0.75
Anxiety/Depression item Standard rTMS 84 2.46 0.50 73 2.15 0.59 76 2.14 0.61 70 1.86 0.64 29 1.86 0.58
Low intensity TBS 104 2.42 0.57 103 2.14 0.61 97 2.03 0.60 88 1.98 0.61 38 1.97 0.64
High intensity TBS 100 2.46 0.50 93 2.15 0.53 89 2.08 0.59 84 2.13 0.66 35 2.09 0.56
Health today Standard rTMS 83 42.94 19.01 72 48.53 20.30 76 51.76 21.02 69 58.83 22.47 29 54.34 22.61
Low intensity TBS 102 43.55 18.43 101 50.82 19.60 96 54.32 18.46 88 56.59 20.72 37 57.16 19.39
High intensity TBS 99 45.54 18.65 92 54.72 18.15 88 53.52 20.92 83 54.17 22.44 36 56.83 18.90
BAI Standard rTMS 33 23.67 13.06 29 17.83 12.69 31 14.06 11.10 29 16.21 13.45 26 17.00 12.88
Low intensity TBS 35 26.06 12.89 38 18.00 12.74 33 16.76 12.16 29 15.59 13.42 29 13.24 12.04
High intensity TBS 39 23.95 11.95 36 18.06 12.82 33 14.09 10.80 30 18.20 11.02 29 13.72 11.38
Anxiety/depression item ¼ anxiety/depression item of The EuroQoL EQ-5D Quality of Life Questionnaire; EQ-5D ¼ Summary indices of The EuroQoL EQ-5D Quality of Life
Questionnaire; QIDS-C16 ¼ Quick Inventory of Depressive Symptomatology e Clinician Rated Version.
QIDS-SR16 ¼ Quick Inventory of Depressive Symptomatology e Self Rated Version.
rTMS ¼ repetitive transcranial magnetic stimulation; SSI ¼ Scale for Suicidal Ideation; TBS ¼ theta burst stimulation.
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significant effect by Time, but not by Treatment Group (Table 7).
3.8. Safety and tolerability
There were no serious adverse events across the treatment
groups. Specifically, there was no induction of seizure or manic
episodes in any participant. Gradual intensity titration to target
suprathreshold intensities during initial stimulation trains/sessions
were necessary in eight participants who received 120 % RMT TBS
and five participants who received 10 Hz rTMS, due to initial
stimulation-induced scalp discomfort. Overall, all three rTMS pro-
tocols were well-tolerated, although four participants allocated toTable 5
QIDS-C16 Treatment response and remission rates at week 4 endpoint.
Group
Combined
L 10 Hz rTMS
BL TBS low intensity




BL TBS low intensity




BL TBS low intensity
BL TBS high intensity
Chi square statistic
Cohort comparison (Inpatients vs. Outpatients)
Chi square statistic
BL ¼ bilateral; Hz ¼ Hertz; L ¼ left-sided.
QIDS-C16 ¼ Quick Inventory of Depressive Symptomatology e Clinician Ra
TBS ¼ theta burst stimulation.
1100the 120 % RMT TBS treatment groupwithdrew due to intolerance of
the stimulation sensation (Fig. 1).
4. Discussion
This study is, to our knowledge, the first large trial of accelerated
bilateral TBS to treat depression and the first to compare the anti-
depressant efficacy between 80 % and 120 % RMT TBS. As detailed in
Tables 3 and 4, patient demographics, diagnoses and baseline
illness severity were comparable across the three treatment
groups, suggestive of minimal likelihood of sampling bias. Notably,
the participants’ psychiatric treatment history indicated particu-
larly treatment-refractory depression, with multiple past trials ofResponse Remission
43.7 % (110/252) 28.2 % (71/252)
51.4 % (37/72) 34.7 % (25/72)
44.1 % (41/93) 26.9 % (25/93)
36.8 % (32/87) 24.1 % (21/87)
3.429, p ¼ 0.180 2.303, p ¼ 0.316
39.6 % (36/91) 29.7 % (27/91)
48.0 % (12/25) 36.0 % (9/25)
44.1 % (15/34) 35.3 % (12/34)
28.1 % (9/32) 18.8 % (6/32)
2.790, p ¼ 0.248 2.824, p ¼ 0.244
46.0 % (74/161) 27.3 % (44/161)
53.2 % (25/47) 34.0 % (16/47)
44.1 % (26/59) 22.0 % (13/59)
41.8 % (23/55) 27.3 % (15/55)
1.455, p ¼ 0.483 1.900, p ¼ 0.387
0.969, p ¼ 0.325 0.157, p ¼ 0.692
ted Version.
Table 6
QIDS-C16 Treatment response and remission rates at week 8.
Group Response Remission
Total 43.5 % (37/85) 29.4 % (25/85)
L 10 Hz rTMS 31.8 % (7/22) 31.8 % (7/22)
BL TBS low intensity 57.6 % (19/33) 27.3 % (9/33)
BL TBS high intensity 36.7 % (11/30) 30.0 % (9/30)
Chi square statistic 4.451, p ¼ 0.108 0.139, p ¼ 0.933
BL ¼ bilateral; Hz ¼ Hertz; L ¼ left-sided.
QIDS-C16 ¼ Quick Inventory of Depressive Symptomatology e Clinician Rated
Version.
TBS ¼ theta burst stimulation.
Fig. 3. QIDS-C16 mean scores: in- and out-patients.
L. Chen, E.H.X. Thomas, P. Kaewpijit et al. Brain Stimulation 14 (2021) 1095e1105antidepressant medications, and/or mood stabiliser or antipsy-
chotic medication augmentation. Approximately half of our par-
ticipants had previously been treated with electroconvulsive
therapy (ECT). Despite the severity, refractoriness and chronicity of
our TRD participants, we found an overall treatment response rate
of 43.7 % (110/252) and remission rate of 28.2 % (71/252).
Our primary outcome was comparison of response and remis-
sion rates across the standard 10 Hz rTMS, accelerated 80 % RMT
bilateral TBS and accelerated 120 % RMT bilateral TBS groups at the
week 4 timepoint. We found no clinically or statistically significant
differences, which suggests overall equivalent rates of categorical
depression response and remission across the three groups, using
pre-defined QIDS-C16 response and remission criteria [50]. In
contrast, post-hoc comparison testing in linear mixed model
analysis of the continuous variables found significantly greater
reduction in QIDS-C16 scores at week 4 in the standard rTMS group
compared with the accelerated bilateral TBS groups. This could
reflect the discrepancies inherent in the categorical and continuous
approaches to measuring depression severity. Whether differences
in treatment completion owing to accelerated and once-daily TBS/
rTMS scheduling introduced a potential confound is discussed
below. Comparing our results with earlier trials, in our pilot study
we similarly found no significant differences in antidepressant ef-
ficacy or rates of adverse effects between accelerated iTBS and
once-daily rTMS [44]. Interestingly, the week 4 response and
remission rates across all three treatment arms in the present study
(36.8e51.4 % response and 24.1e34.7 % remission) were consider-
ably higher than our pilot investigation (26.3e27.8 % response and
8.3e13.2 % remission), despite equivalent coil localisation tech-
niques and 10 Hz rTMS parameters. These differences could be
attributable to the present study's larger sample size and therefore
statistical power, the different depression rating scales employed
(QIDS-C16 versus the Montgomery Åsberg Depression Rating Scale)
and, possibly, the additional therapeutic efficacy of bilateral TBS
over unilateral iTBS, although this remains to be validated. With
respect to other trials evaluating bilateral TBS's antidepressantFig. 2. QIDS-C16 mean scores over time.
1101efficacy in TRD, Li et al. reported 66.7 % responders (10/15), which
was higher than the 40.0 % (6/15) of responders who received iTBS
alone [60]. Br€oker et al.’s case series of accelerated iTBS reported
depression response in 55.6 % (5/9) of participants. However, both
studies featured considerably smaller sample sizes, precluding like-
for-like comparison. Indeed, comparing our results with published
accelerated TBS trials has proven challenging given the paucity of
comparable trials and, perhaps more importantly, variability in TBS
scheduling and dosing parameters [45,46,61]. To this end, our
overall response and remission rates of 43.7 % and 28.2 % respec-
tively, were arguably most comparable with those reported in the
THREE-D study: 47.4 % (91/192) responders and 26.6 % (51/192)
remitters in the 10 Hz rTMS group, and 49.2 % (95/193) responders
and 31.6 % (61/193) remitters in the iTBS group using the 17-item
Hamilton Depression Rating Scale [22].
The brevity of TBS paradigms over conventional 37.5-min 10 Hz
rTMS protocols confer clear efficiency and health economic ad-
vantages [62]. Applying TBS in our accelerated schedule saw to
additional time efficiency and markedly reduced the number of
occasions patients needed to attend our treatment centres. How-
ever, we did not find faster reduction of depression severity with
the accelerated application of bilateral TBS compared to a con-
ventional 4-week rTMS approach. This could be explained by Kaster
et al.’s depressive symptom trajectory modelling in rTMS [63]. The
same four distinct symptom response trajectories were observed
when the model was applied to outcomes from our pilot acceler-
ated iTBS versus once-daily rTMS trial, suggesting that rate of an-
tidepressant response was not associated with accelerated
treatment scheduling [64]. Nonetheless, the delivery of 20 TBS
sessions in a more time-efficient manner offers appreciable con-
venience and practical advantages for patients and TMS services.
The inter-session interval specified in our accelerated bilateral
TBS protocol warrants discussion, given its relevance when
scheduling more than one TBS session per day and how differentFig. 4. BAI mean scores over time.
Table 7
Linear mixed model analysis of secondary outcome measures.
Assessment Effect over time P value Effect by treatment group P value
QIDS-SR16 F (4, 194.37) ¼ 105.91 <0.001 F (2, 275.25) ¼ 0.35 0.71
BAI F (4, 87.45) ¼ 25.11 <0.001 F (2, 109.59) ¼ 0.01 1.00
SSI F (4189.29) ¼ 31.56 <0.001 F (2, 279.41) ¼ 1.41 0.25
EQ-5D F (4, 191.87) ¼ 40.51 <0.001 F (2, 279.64) ¼ 0.18 0.83
BAI ¼ Beck's Anxiety Inventory (21-item self-report).
EQ-5D ¼ Summary indices of The EuroQoL EQ-5D Quality of Life Questionnaire; QIDS-SR16 ¼ Quick Inventory of Depressive Symptomatology e Self Rated Version.
SSI ¼ Scale for Suicidal Ideation.
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ditioning and thereby, therapeutic effects. Animal models have
shown 1-h intervals between iTBS sessions were necessary for the
induction of neuroplastic changes [65], while a study in healthy
adults found single- or double-session iTBS applied at 8- or 15-min
intervals had no motor cortical excitatory effects [66]. In their re-
view, Smolen et al. suggested 40-60-min intervals are needed be-
tween successive theta-burst stimuli to increase neuronal long-
term potentiation (LTP) effects and that this may be explained by
the initial stimulus's priming effects on dendritic spines before the
subsequent stimulus is applied [67]. It is worth considering, how-
ever, that findings from experiments evaluating rTMS/TBS's effects
on motor cortical excitability may not be extrapolatable to effects
on the prefrontal cortex. Likewise, how TMS-induced changes in
synaptic plasticity implicate treatment of depressive symptoms
remains an area of ongoing investigation. Few depression studies
have specifically investigated this aspect of TBS/rTMS's stimulation
parameters. As such, the optimal TBS inter-session or rTMS intra-
session/inter-train intervals for the purpose of induction of thera-
peutic effects remain undetermined [68]. With respect to inter-
train interval's effects on antidepressant efficacy in 10 Hz rTMS,
Carpenter et al. recently reported minimal differences in depres-
sion response and remission rates from a large multi-site registry
between patients who received standard and a ‘Dash’ rTMS pro-
tocol that featured shorter inter-train intervals [69]. Our study's 15-
min TBS inter-session interval mirrored the protocol of our pilot
trial [44] and our earlier motor cortical conditioning studies [70,71].
In designing this study, the 15-min interval between three suc-
cessive bilateral TBS sessions was also in-part chosen with the aim
of developing a treatment schedule that could be implemented
within an hour and hence align with schedules in a clinical TMS
service. Administering three bilateral TBS treatments 45- to 60-min
apart could have been practically challenging and inefficient in such
settings, particularly for outpatient clinical services. Nonetheless, it
remains unclear if longer inter-session intervals, a la the Stanford
Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol
[45,61], might have yielded different treatment outcomes for our
trial participants.
Prior to the present study, little was known about the optimal
TBS intensity relative to RMT for the treatment of depression.
Preclinical studies investigating the neuronal conditioning effects
of various TBS stimulation intensities on the prefrontal [38] and
motor [37] cortices suggested sub- or near-threshold stimulation
intensities were associated with significant neuronal conditional
effects. The putative physiological basis for this is beyond the scope
of this discussion, but was explored by Di Lazarro et al. [72,73] and
postulated to be due to near-threshold TMS's preferential activation
of interneurons via axonal projections. In our comparison of anti-
depressant efficacy between sub- and supra-threshold TBS, we did
not find clinically or statistically significant differences between the
80 % RMT and 120 % RMT TBS arms. However, we observed that
participants were more likely to find the scalp sensation associated
with 120 % RMT TBS pulses difficult to tolerate. Given the1102comparable therapeutic efficacy observed here, sub-threshold TBS
may be considered a viable TBS alternative to 120 % RMT TBS,
especially for those patients unable to tolerate supra-threshold TBS.
Evaluation of the QIDS-C16 and QIDS-SR16 measures at week 4
suggest 10 Hz rTMS had superior antidepressant efficacy over the
accelerated bilateral TBS approaches (Table 4, Figs. 2 and 3.),
although the magnitude of depression symptom amelioration was
less noticeable by week 8 follow-up. This observation might be
explained by the earlier course discontinuation for patients
receiving accelerated bilateral TBS, whereas patients who received
the standard 4-week rTMS course benefitted from continuation of
trial participation, clinic attendances and rTMS sessions. Discharge
of inpatient participants after completion of accelerated bilateral
TBS courses may also have seen to earlier relapse of depression in
some susceptible patients relative to those continuingwith 4weeks
of 10 Hz rTMS therapy, particularly as our trial protocol did not offer
completed participants any form of tapering or maintenance rTMS/
TBS. Alternatively, it is possible that 20 sessions of bilateral TBS
delivered over 10 days was an insufficient dose, in view of the
notion that TRD non-responsive to rTMS may be attributable to
under-dosing [61] and that patients with highly refractory
depression may benefit from more TMS pulses per day [30] and/or
more total pulses per course [74]. In contrast to the bilateral
cTBS600 and iTBS600 we applied over 20 sessions (equating to a
total of 24,000 TBS pulses), Williams et al. reported favourable
treatment response rates in both TRD [45,61] and obsessive-
compulsive disorder [75] when 50 sessions of iTBS1800 were
applied (totalling 90,000 pulses). Further, Nettekoven et al. found
increased motor cortical excitability of iTBS1800 over iTBS600 and
iTBS1200 protocols in healthy controls [37]. A more recent study
evaluating various pulse counts of iTBS and cTBS found the higher
pulse count iTBS1200 and cTBS3600 protocols were more effective
in modulating motor cortical excitability, although high within and
between subject variability were reported [76]. It is also unclear
how pulse counts affecting TBS or rTMS's motor cortical condi-
tioning effects in healthy controls relate to its antidepressant effi-
cacy when applied to the prefrontal cortices to treat TRD. The
counterargument to a pulse count-dependent response relation-
ship applying rTMS to treat TRD is the finding of no consistent as-
sociation between antidepressant response and the number of
rTMS pulses applied over courses of high-/standard-dose 10 Hz
rTMS and high-/standard-dose 1 Hz rTMS in a recent multi-site trial
[77].
Despite high rates of comorbidity between anxiety and
depression [78] and the overlap in implicated brain regions in the
two conditions [79,80], studies specifically addressing rTMS's
therapeutic efficacy in primary anxiety disorders have reported
equivocal results [81e84]. Limited research exists describing
rTMS's efficacy in treating comorbid anxiety in depression,
although recent analyses report comparable anxiolytic efficacy
across the commonly applied rTMS protocols [85,86]. Less is known
about TBS's anxiolytic potential in MDD, although a sub-analysis of
anxiety outcomes from THREE-D point to therapeutic equivalence
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provided preliminary evaluation of accelerated bilateral TBS's ef-
fects on anxiety symptoms occurring in depression. To this end, we
found no significant difference across the 10 Hz rTMS and bilateral
TBS approaches (p ¼ 1.00) (Table 7).
There are several limitations to the interpretation of our study
results. First, we compared bilateral TBS with unilateral 10 Hz rTMS.
In the interest of controlling for heterogeneity in the interventions
applied, comparisons of accelerated bilateral TBS with once-daily
bilateral rTMS or accelerated unilateral iTBS with once-daily uni-
lateral 10 Hz rTMS could have been preferred alternatives. How-
ever, literature available at the time of study conceptualisation
suggested that bilateral cTBS/iTBS may be more effective than
unilateral iTBS alone [30]. Our intention was to design a definitive
depression treatment trial comparing what was then-thought to be
a potentially superior TBS protocol against a standard, ‘treatment as
usual’ 10 Hz rTMS protocol as the active control. From this
perspective, a comparison of bilateral TBS and unilateral rTMS was
conceived. Due to the scheduling differences between the acceler-
ated bilateral TBS and once-daily rTMS protocols, the week 4
endpoint assessment for participants allocated to the former
treatment took place 18-days after course completion and, for those
allocated to once-daily rTMS, at course completion, thereby intro-
ducing the confound associated with treatment/clinic attendance
to the interpretation of our results. A second issue arising from
scheduling differences was our inability to blind participants to
their treatment allocations thereby possibly introducing expecta-
tion bias. Although we endeavoured to keep the assessors blinded
by repeatedly reminding participants not to disclose their treat-
ment group, systematic assessment of blinding was not carried out.
Our trial did not feature a sham control arm, although this would
not have been feasible or ethically justifiable given the study was
conducted at busy clinical centres and participants were prag-
matically recruited from moderate-to-severe TRD patients pre-
senting for treatment, many with associated clinical risks. Given
our primary outcome was the comparison of depression treatment
response across the three TBS/rTMS protocols, the lack of sham
control could still be considered an appropriate design for the
purpose of our investigation. Whilst the participants' past antide-
pressant trials were recorded as numerical measures (Table 3), we
did not curate the names and classes of antidepressants trialled, eg.
through use of the Antidepressant Treatment History Form (ATHF)
or similar instrument, thereby precluding correlation analysis of
treatment response and the types of antidepressants tried. Further,
although non-antidepressant concomitant medications were noted
in a binary fashion (Table 3), we did not collate more detailed data
such as the type of mood stabiliser medication (lithium or anti-
convulsant mood stabilisers), concomitant benzodiazepine
administration or the doses and treatment durations of these
medications. This omission may be of relevance given these med-
ications' possible influences on cortical excitability and therefore
rTMS response [88,89], and in view of the literature that emerged
since this study's conceptualisation that discuss the impact
concomitant benzodiazepines might have on antidepressant
response to rTMS [90e92]. Additionally, we did not systematically
record tolerability issues expected with rTMS therapy, eg. head-
aches, head/facial muscle twitches, tiredness, etc., precluding
quantitative comparison of these side effects across the three rTMS
approaches. Lastly, being a multi-centre study, we were unable to
control for potential variations in performance of the stimulators
and coils used, which may be particularly relevant for rTMS applied
at theta-burst frequency on the basis of power roll-off with rapid
(50 Hz) sequential pulse discharges. This is a potential confound for
all rTMS studies where 2 or more rTMS systems are used. To this
end, we clarified with the respective stimulator manufacturers that1103both systems share comparable power roll-off properties at triplet/
50 Hz stimulation when applied at 50e55 % power intensity or
more. Further, we mitigated this potential confound by standard-
izing coil localisation and RMT measurement methods and stimu-
lation protocols.
In conclusion, this study provides evidence that accelerated
bilateral TBS is effective and safe in the treatment of TRD. Bilateral
sequential cTBS/iTBS did not infer superior antidepressant effect
over left unilateral 10 Hz rTMS. The brevity of TBS was well-suited
to application in accelerated schedules. Despite the clinical effi-
ciency of our 10-day accelerated bilateral TBS protocol and its
popularity with patients, there was no convincing evidence it
resulted in more rapid amelioration of depression severity
compared to a conventional 4-week rTMS course. We found no
significant difference in anxiolytic efficacy across the accelerated
bilateral TBS and daily unilateral 10 Hz rTMS groups. As a pre-
liminary attempt to compare the antidepressant efficacy of 80 %
and 120 % RMT TBS, the therapeutic equivalence we observed
suggest further research is needed to elucidate what effects TBS
intensity has on antidepressant efficacy. In the meantime, sub-
threshold TBS may be an alternative to suprathreshold TBS for
patients unable to tolerate the cutaneous sensations associated
with the latter, although this warrants prospective validation.
Future accelerated TBS trials adopting large, double-blind, sham-
controlled study design can consolidate its antidepressant potential
and define its role in the limited armamentarium of effective
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